Reply to: "COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated".
J Am Acad Dermatol
; 87(1): e47-e48, 2022 07.
Article
in En
| MEDLINE
| ID: mdl-35364217
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Rheumatic Diseases
/
Antirheumatic Agents
/
Rituximab
/
COVID-19 Vaccines
/
COVID-19
Limits:
Humans
Language:
En
Journal:
J Am Acad Dermatol
Year:
2022
Document type:
Article